Impact of neoadjuvant androgen deprivation therapy on toxicity in intensity-modulated radiation therapy for prostate cancer

• DOI: 10.1093/jrr/rrae056
• Publication Date: 2024-08-18T18:54:02Z
• Authors: Itsuko Serizawa; Takuyo Kozuka; Takashi Soyano; Kazuma Sasamura; Tatsuya Kamima; Hiroaki Kunogi; Noboru Numao; Shinya Yamamoto; Junji Yonese; Yasuo Yoshioka
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Oncology/Medicine

Abstract This study aimed to compare toxicities, prostate volume and dosimetry, between patients who underwent intensity-modulated radiation therapy (IMRT) combined with ≥3 months of neoadjuvant androgen deprivation (NADT) those without NADT for cancer. In total, 449 intermediate- high-risk cancer received 78 Gy IMRT in 39 fractions, which 129 were treated any ADT (non-ADT group) 320 (NADT group). Adverse events dose-volume indices compared the two groups retrospectively. The group had a lower rate acute grade 2 gastrointestinal (GI) toxicities (17% vs 25%, P = 0.063) late GI (P 0.055), including significantly rectal hemorrhage 0.033), non-ADT group. There no cases 3 or higher toxicities. average was 38% smaller than that (43.7 27.0 cm3, < 0.001). Bladder V40Gy V50Gy, rectum V40Gy, V60Gy V70Gy group, significant difference observed adverse dosimetry subgroups ≥12 <12 months. Acute reduced by within accordance improved dosimetry. suggests merit administering reducing